PCM
BMRN icon

Price Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Price Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,145
Closed -$267K – 30
2015
Q1 		$267K Buy
+2,145
New +$227K 0.17% 133

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Price Capital Management's BMRN Position: Q2 2015 in Review

Price Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 2,145 shares — an estimated $267K sold.

Price Capital Management first reported a position in BMRN in Q1 2015 and held it in 1 quarter. The position peaked at $267K in Q1 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

  • Price Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 2,145 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $267K.
  • Price Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's BioMarin Pharmaceuticals position peaked at $267K in Q1 2015.
  • 391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.